Abstract

PurposeIdentifying among nephroblastoma those with a high propensity for distant metastases using cell cycle markers: cyclin E as a regulator of progression through the cell cycle and Ki-67 as a tumor proliferation marker, since both are often deregulated in many human malignancies.Methodology/Principal FindingsA staining index (SI) was obtained by immunohistochemistry using anti-cyclin E and anti-Ki-67 antibodies in paraffin sections of 54 postchemotherapy nephroblastoma including 42 nephroblastoma without metastasis and 12 with metastases. Median cyclin E and Ki-67 SI were 46% and 33% in blastemal cells, 30% and 10% in stromal cells, 37% and 29.5% in epithelial cells. The highest values were found for anaplastic nephroblastoma. A correlation between cyclin E and Ki-67 SI was found for the blastemal component and for the epithelial component. Univariate analysis showed prognostic significance for metastases with cyclin E SI in stromal cells, epithelial cells and blastemal cells (p = 0.03, p = 0.01 and p = 0.002, respectively) as well as with Ki-67 SI in blastema (p<10−4). The most striking data were that both cyclin E SI and blastemal Ki-67 SI discriminated between patients with metastases and patients without metastasis among intermediate-risk nephroblastoma.ConclusionsOur findings show that a high cyclin E SI in all components of nephroblastoma is correlated with tumor aggressiveness and metastases, and that assessment of its expression may have prognostic value in the categorization of nephroblastoma.

Highlights

  • Nephroblastoma is the most common pediatric tumor of the kidney [1]

  • Our findings show that a high cyclin E staining index (SI) in all components of nephroblastoma is correlated with tumor aggressiveness and metastases, and that assessment of its expression may have prognostic value in the categorization of nephroblastoma

  • In Europe, patients are treated according to the International Society of Pediatric Oncology (SIOP) protocol, which consists of preoperative chemotherapy and surgical resection followed by postoperative treatment [2]

Read more

Summary

Introduction

Nephroblastoma is the most common pediatric tumor of the kidney [1]. It arises from metanephric blastemal cells and recapitulates renal embryogenesis. In Europe, patients are treated according to the International Society of Pediatric Oncology (SIOP) protocol, which consists of preoperative chemotherapy and surgical resection followed by postoperative treatment [2]. This latter step is adjusted on the basis of tumor histology and local tumor stage. Stage I low-risk nephroblastoma receive no postoperative treatment while high-risk tumors (i.e. diffuse anaplasia and blastemal types) are treated with aggressive chemotherapy. There is still a need for accurate molecular prognostic markers to identify these intermediate-risk tumors that need more intensive treatment

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call